Vaccine-Induced tumor necrosis factor- Producing T cells synergize with cisplatin to promote tumor cell death

Clinical Cancer Research

Volumn 21, Issue 4, 2015, Pages 781-794

  Van Der Sluis, Tetje C ^a   Van Duikeren, Suzanne ^a   Huppelschoten, Suzanna ^b   Jordanova, Ekaterina S ^c   Nejad, Elham Beyranvand ^a   Sloots, Arjen ^a   Boon, Louis ^d   Smit, Vincent T H B M ^a   Welters, Marij J P ^a   Ossendorp, Ferry ^a   Van De Water, Bob ^d   Arens, Ramon ^a   Van Der Burg, Sjoerd H ^a   Melief, Cornelis J M ^a,e  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b LEIDEN UNIVERSITY   (Netherlands)

^c VU UNIVERSITY AMSTERDAM   (Netherlands)

^d BIOCEROS   (Netherlands)

^e ISA Pharmaceuticals   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARBOPLATIN; CISPLATIN; DOXORUBICIN; GAMMA INTERFERON; GEMCITABINE; OXALIPLATIN; PACLITAXEL; PEPTIDE VACCINE; TOPOTECAN; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; PEPTIDE; TNF PROTEIN, HUMAN; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOTINYLATION; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL DEATH; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ERADICATION; DRUG POTENTIATION; DRUG SENSITIVITY; FEMALE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS TYPE 16; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; UPREGULATION; UTERINE CERVIX CANCER; ADOPTIVE TRANSFER; ANIMAL; BIOSYNTHESIS; C57BL MOUSE; COMPLICATION; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; PAPILLOMAVIRUS INFECTION; PATHOLOGY; TUMOR ASSOCIATED LEUKOCYTE; UTERINE CERVIX TUMOR; VIROLOGY;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC AGENTS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL DEATH; CISPLATIN; DISEASE MODELS, ANIMAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED C57BL; PAPILLOMAVIRUS INFECTIONS; PEPTIDES; REAL-TIME POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA; UTERINE CERVICAL NEOPLASMS; VIRAL PROTEINS;

EID: 84923138991     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-2142     Document Type: Article

References (47)

1. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survivalwith ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711-23.
2. Kantoff PW, Schuetz TJ, Blumenstein BA, Glode LM, Bilhartz DL, Wyand M, et al. Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targetedimmunotherapy inmetastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-105.
3. Small EJ, Schellhammer PF, Higano CS, Redfern CH, Nemunaitis JJ, Valone FH, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 2006;24:3089-94.
4. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12:878-87.
5. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al. A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9.
6. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
7. Casares N, Pequignot MO, Tesniere A, Ghiringhelli F, Roux S, Chaput N, et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005;202:1691-701.
8. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death.Nat Med 2007;13:54-61.
9. Kang TH, Mao CP, Lee SY, Chen A, Lee JH, Kim TW, et al. Chemotherapy acts as an adjuvant to convert the tumor microenvironment into a highly permissive state for vaccination-induced antitumor immunity. Cancer Res 2013;73:2493-504.
10. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update. Int J Cancer 2007;121:621-32.
11. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, et al. Prevalence of human papillomavirus in cervical cancer: A worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995;87:796-802.
12. Melief CJ, Toes RE, Medema JP, van-der-Burg SH, Ossendorp F, Offringa R. Strategies for immunotherapy of cancer. Adv Immunol 2000;75: 235-82.
13. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van-der-Meer DM, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009;361:1838-47.
14. Van-Duikeren S, Fransen MF, Redeker A, Wieles B, Platenburg G, Krebber WJ, et al. Vaccine-induced effector-memory CD8 T cell responses predict therapeutic efficacy against tumors. J Immunol 2012;189:3397-403.
15. Zwaveling S, Ferreira-Mota SC, Nouta J, Johnson M, Lipford GB, Offringa R, et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002;169:350-8.
16. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van-der-Meer DM, Vloon AP, et al. Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity. Clin Cancer Res 2008;14:169-77.
17. Van-Poelgeest MI, Welters MJ, van-Esch EM, Stynenbosch LF, Kerpershoek G, van-Persijn-van-Meerten EL, et al. HPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial. J Transl Med 2013;11:88.
18. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6.
19. Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitopecontaining peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol 1993;23:2242-9.
20. Winzler C, Rovere P, Rescigno M, Granucci F, Penna G, Adorini L, et al. Maturation stages of mouse dendritic cells in growth factor-dependent long-term cultures. J Exp Med 1997;185:317-28.
21. Arens R, Loewendorf A, Her MJ, Schneider-Ohrum K, Shellam GR, Janssen E, et al. B7-mediated costimulation of CD4 T cells constrains cytomegalovirus persistence. J Virol 2011;85:390-6.
22. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, Offringa R, van der Burg SH. CD8 CTL priming by exact peptide epitopes in incomplete Freund's adjuvant induces a vanishing CTL response, whereas long peptides induce sustained CTL reactivity. J Immunol 2007;179:5033-40.
23. Puigvert JC, de BH, van de Water B, Danen EH. High-throughput live cell imaging of apoptosis. Curr Protoc Cell Biol 2010;Chapter 18:Unit-13.
24. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ, Montero AJ. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. CancerImmunol Immunother 2009;58:49-59.
25. Gupta R, Babb JS, Singh B, Chiriboga L, Liebes L, Adams S, et al. The numbers of FoxP3 lymphocytes in sentinel lymph nodes of breast cancer patients correlate with primary tumor size but not nodal status. Cancer Invest 2011;29:419-25.
26. Baak JP, van-Diest PJ, Voorhorst FJ, van-der Wall E, Beex LV, Vermorken JB, et al. Prospective multicenter validation of the independent prognostic value of the mitotic activity index in lymph node-negative breast cancer patients younger than 55 years. J Clin Oncol 2005;23:5993-6001.
27. Deng Y, Ren X, Yang L, Lin Y, Wu X. A JNK-dependent pathway is required for TNFalpha-induced apoptosis. Cell 2003;115:61-70.
28. Benedetti G, Fredriksson L, Herpers B, Meerman J, van de Water B, de GM. TNF-alpha-mediated NF-kappaB survival signaling impairment by cisplatin enhances JNK activation allowing synergistic apoptosis of renal proximal tubular cells. Biochem Pharmacol 2013;85:274-86.
29. Braumuller H, Wieder T, Brenner E, Assmann S, Hahn M, Alkhaled M, et al. T-helper-1-cell cytokines drive cancer into senescence. Nature 2013;494: 361-5.
30. Zhou F, Chen J, Zhao KN. Human papillomavirus 16-encoded E7 protein inhibits IFN-gamma-mediated MHC class I antigen presentation and CTLinduced lysis by blocking IRF-1 expression in mouse keratinocytes. J Gen Virol 2013;94:2504-14.
31. Lejeune FJ, Lienard D, Matter M, Ruegg C. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun 2006;6:6.
32. Van-Horssen R, Ten-Hagen TL, Eggermont AM. TNF-alpha in cancer treatment: molecular insights, antitumor effects, and clinical utility. Oncologist 2006;11:397-408.
33. Sacchi A, Gasparri A, Gallo-Stampino C, Toma S, Curnis F, Corti A. Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha. Clin Cancer Res 2006;12:175-82.
34. Baker SJ, Reddy EP. Modulation of life and death by the TNF receptor superfamily. Oncogene 1998;17:3261-70.
35. Beutler B, Cerami A. Cachectin and tumour necrosis factor as two sides of the same biological coin. Nature 1986;320:584-8.
36. Zhang B, Ramesh G, Norbury CC, Reeves WB. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. Kidney Int 2007;72:37-44.
37. Bae SH, Park YJ, Park JB, Choi YS, Kim MS, Sin JI. Therapeutic synergy of human papillomavirus E7 subunit vaccines plus cisplatin in an animal tumor model: causal involvement of increased sensitivity of cisplatintreated tumors to CTL-mediated killing in therapeutic synergy. Clin Cancer Res 2007;13:341-9.
38. Peng S, Trimble C, Alvarez RD, Huh WK, Lin Z, Monie A, et al. Cluster intradermal DNA vaccination rapidly induces E7-specific CD8 T-cell immune responses leading to therapeutic antitumor effects. Gene Ther 2008;15:1156-66.
39. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. J Clin Invest 2010; 120:1111-24.
40. Sin JI, Kim JM, Bae SH, Lee IH, Park JS, Ryoo HM. Adoptive transfer ofhuman papillomavirus E7-specific CTL enhances tumor chemoresponse through the perforin/granzyme-mediated pathway. Mol Ther 2009;17:906-13.
41. Chen S, Liao C, Lai Y, Fan Y, Lu G, Wang H, et al. De-oncogenic HPV E6/E7 vaccine gets enhanced antigenicity and promotes tumoricidal synergy with cisplatin. Acta Biochim Biophys Sin 2014;46:6-14.
42. Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010;18:1947-59.
43. Lee SY, Kang TH, Knoff J, Huang Z, Soong RS, Alvarez RD, et al. Intratumoral injection of therapeutic HPV vaccinia vaccine following cisplatin enhances HPV-specific antitumor effects. Cancer Immunol Immunother 2013;62:1175-85.
44. Tseng CW, Hung CF, Alvarez RD, Trimble C, Huh WK, Kim D, et al. Pretreatment with cisplatin enhances E7-specific CD8 T-cell-mediated antitumor immunity induced by DNA vaccination. Clin Cancer Res 2008;14:3185-92.
45. Cao W, Chi WH, Wang J, Tang JJ, Lu YJ. TNF-alpha promotes Doxorubicininduced cell apoptosis and anti-cancer effect through downregulation of p21 in p53-deficient tumor cells. Biochem Biophys Res Commun 2005;330:1034-40.
46. Ma Y, Yamazaki T, Yang H, Kepp O, Galluzzi L, Zitvogel L, et al. Tumor necrosis factor is dispensable for the success of immunogenic anticancer chemotherapy. Oncoimmunology 2013;2:e24786.
47. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013;31:51-72.